Finland

Blossom currently tracks 10 psychedelic clinical trials connected to Finland. The country page also links to 2 stakeholders and 2 events, giving the page ecosystem context beyond registered studies.

Ask Blossom about this country

Data updated July 15, 2026

Key Insights

A concise view of the policy, research, access, and stakeholder details shaping psychedelic medicine inFinland.

1
Blossom tracks 10 psychedelic clinical trials connected to Finland, with none currently marked active.
2
Visible trial compounds include Esketamine, Ketamine and Psilocybin.
3
Visible trial topics include Treatment-Resistant Depression (TRD), Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD).
4
The country page links to 2 stakeholders and 2 events in Blossom's ecosystem data.
5
The country access guide currently classifies access as "Medical Only (Private)"; details vary by compound and care setting.

Research and Access Snapshot

Blossom currently tracks 10 psychedelic clinical trials connected to Finland.

Active trials: 0
Total trials: 10
Stakeholders: 4
Events: 3

Top Compounds

Esketamine(6)
Ketamine(3)
Psilocybin(2)

Medical Access

Finland maintains a restrictive controlled-substance regime: pharmaceutical esketamine (Spravato) is an authorised medicine in the EU and available in Finland under prescription and supervised administration, while generic ketamine is an established medical anaesthetic (and occasionally used off-label in psychiatric emergency settings) but psychedelic classical compounds (psilocybin, MDMA, DMT, 5-MeO-DMT, ibogaine, ayahuasca/DMT plant preparations, mescaline, and 2C-X) are scheduled as narcotics with no routine medical reimbursement except in authorised...

View trials→View stakeholders→View events→Open access guide→

Research Landscape

What the 10 registered trials connected to Finland look like when you line them up. Counts come from Blossom’s trial records as of July 2026.

How fast is Finland research growing?

Sourced

Registered trials by recorded study-start year; 1 earlier trial began before 2010. Click a year for the running total.

3trials began in 2015

4 started by 2015

Browse trials→

Don't read as total research effort: only registered trials with a recorded start date are counted (10 of 10 tracked). Recent years under-count because of registration lag; striped bars are still filling in or are planned starts.

What's live right now, and what stopped?

Sourced

Registry status of all 10 Finland trials Blossom tracks. Orange marks trials recruiting or opening.

Completed: 660%
Stopped early: 330%
Unknown / other: 110%

Browse trials →

Don't read stopped trials as failures: trials end early for funding, recruitment, and strategy reasons too. Status is as last synced from the registry; some 'recruiting' trials may already have finished.

Which compounds does Finland study?

Sourced

Trials per compound. Orange marks the most-studied compound.

Esketamine

Ketamine

Psilocybin

Don't read shares as adding to 100%: a trial testing several compounds counts once per compound, and placebo comparator arms are not shown. Trial volume signals research attention, not evidence quality.

Regulatory Status

The linked medical access and reimbursement guide summarises Finland as "Medical Only (Private)". Finland maintains a restrictive controlled-substance regime: pharmaceutical esketamine (Spravato) is an authorised medicine in the EU and available in Finland under prescription and supervised administration, while generic ketamine is an established medical anaesthetic (and occasionally used off-label in psychiatric emergency settings) but psychedelic classical compounds (psilocybin, MDMA, DMT, 5-MeO-DMT, ibogaine, ayahuasca/DMT plant preparations, mescaline, and 2C-X) are scheduled as narcotics with no routine medical reimbursement except in authorised clinical research. Reimbursement of any medicine in Finland is governed by decisions of the Pharmaceuticals Pricing.